Catalyst Crew Technologies Corp. has announced the development of PulmoAI, an artificial intelligence-enabled module designed to support the detection and predictive analysis of pulmonary diseases. The platform is intended to assist healthcare providers in analyzing respiratory health data and identifying potential clinical risks through artificial intelligence-driven analytics.
PulmoAI's proposed capabilities include automated interpretation of thoracic imaging, detection of pulmonary abnormalities, and predictive modeling of disease progression. The platform is being developed to integrate multiple data inputs, including computed tomography scans, chest X-rays, pulmonary function tests, and inflammatory biomarkers, in order to generate structured outputs intended to support clinical review and care coordination.
The development of PulmoAI represents a significant advancement in applying artificial intelligence to respiratory healthcare, particularly in regions where access to specialized diagnostics may be limited. The platform forms part of the Company's broader artificial intelligence healthcare platform and is expected to function as a specialized module within Catalyst Crew's digital health ecosystem. Management believes that modular AI systems, such as PulmoAI, may support scalable deployment across telehealth services, remote diagnostics, and technology-enabled healthcare delivery environments.
Catalyst Crew Technologies intends to prioritize market development in Latin America, where the Company believes artificial intelligence-enabled healthcare technologies may help expand access to respiratory diagnostics, support earlier identification of pulmonary conditions, and improve healthcare system efficiency. The Company intends to integrate PulmoAI across its existing and planned healthcare infrastructure initiatives, including its healthcare services coordination platform. As development progresses, PulmoAI is expected to support early detection capabilities and data-driven insights across multiple points of care.
Dr. Kevin Rodan Levy, Chief Executive Officer of Catalyst Crew Technologies Corp., stated that artificial intelligence has the potential to enhance how healthcare providers detect and monitor pulmonary conditions. The Company intends to continue developing and refining PulmoAI and its broader healthcare technology platform while evaluating opportunities for pilot programs, strategic partnerships, and phased market deployment. For more information about the Company's initiatives, please visit https://catalystcrewai.com or review the Company's filings with the U.S. Securities and Exchange Commission at https://www.sec.gov.
The introduction of PulmoAI addresses a critical need in global healthcare systems, particularly in emerging markets where respiratory diseases represent a significant burden. By leveraging artificial intelligence to analyze multiple data sources, the platform could potentially reduce diagnostic delays and improve treatment outcomes for patients with pulmonary conditions. The technology's focus on predictive modeling represents an important shift toward proactive healthcare management, moving beyond simple detection to anticipating disease progression and optimizing intervention strategies.
This development comes at a time when healthcare systems worldwide are seeking technological solutions to address workforce shortages, improve diagnostic accuracy, and expand access to specialized care. The platform's modular design suggests potential for adaptation to other medical specialties, though initial deployment will concentrate on respiratory health applications. The emphasis on Latin American markets reflects both regional healthcare needs and the Company's strategic positioning in emerging economies where digital health infrastructure is rapidly evolving.
